FindTrial
Sign In

Comparison of different discontinuation methods of antithyroid drugs on Graves' disease: A prospective randomized clinical trial with long-term follow-up

Comparison of three discontinuation dose of methimazole on Graves' disease: A prospective randomized clinical trial with long-term follow-up

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-13003306
Enrollment
Unknown
Registered
2013-05-29
Start date
1999-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves’ disease

Interventions

A:methimazole therapy with 5mgqd at drug withdrawal
B:methimazole therapy with 2.5mgqd at drug withdrawal
C:methimazole therapy with 2.5mgqod at drug withdrawal

Sponsors

First Affiliated Hospital of Xi’an Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 73 Years

Inclusion criteria

Inclusion criteria: 1. Graves' disease; 2. All patients were first diagnosed and none of the patients had been treated for Graves' disease prior to inclusion.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients combined with thyroid tumor or thyroiditis; 3. Patients who is more suitable for radioiodine or surgery; 4. Serious hepatic impairment or agranulocytosis; 5. Patients after thyroid surgery or radioiodine therapy.

Design outcomes

Primary

MeasureTime frame
TSH;FT3;FT4;TT3;TT4;TMAb;TGAb;TPOA;—

Countries

China

Contacts

Public ContactBingyin Shi
shibingy@126.com+86 029-85323974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026